Riluzole sublingual - Biohaven Pharmaceutical

Drug Profile

Riluzole sublingual - Biohaven Pharmaceutical

Alternative Names: BHV-0223

Latest Information Update: 08 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Yale University
  • Developer Biohaven Pharmaceutical Holding Company; Yale University
  • Class Benzothiazoles; Neuroprotectants; Small molecules; Thiazoles
  • Mechanism of Action Glutamate modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis; Spinocerebellar degeneration
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Social phobia
  • Phase I Generalised anxiety disorder; Mood disorders
  • Clinical Phase Unknown Amyotrophic lateral sclerosis

Most Recent Events

  • 06 Nov 2017 Clinical trials in Amyotrophic lateral sclerosis in USA (Sublingual)
  • 01 Nov 2017 US FDA approves IND application for riluzole sublingual in Amyotrophic lateral sclerosis
  • 14 Aug 2017 Biohaven plans a bioequivalence trial for Amyotrophic lateral sclerosis in USA (Sublingual) in the fourth quarter of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top